Personalized Medicine Universe最新文献_第6页

On molecularly personalized medicine clinical trials 分子个体化医学临床试验

Personalized Medicine Universe Pub Date : 2017-07-01 DOI: 10.1016/j.pmu.2016.10.002

Reza Sanaye, Babak Daneshfard

引用次数: 1

On the neuronal connectivity of our thoughts into actions 我们的思想和行动之间的神经元连接

Personalized Medicine Universe Pub Date : 2016-07-01 DOI: 10.1016/j.pmu.2015.11.001

Jack Kushner

引用次数: 1

Discussion of current ethical issues regarding the use of assisted reproductive treatment in Japan 讨论当前在日本使用辅助生殖治疗的伦理问题

Personalized Medicine Universe Pub Date : 2016-07-01 DOI: 10.1016/j.pmu.2016.05.001

Hitomi Irizawa, Akinobu Gotoh

{"title":"Discussion of current ethical issues regarding the use of assisted reproductive treatment in Japan","authors":"Hitomi Irizawa, Akinobu Gotoh","doi":"10.1016/j.pmu.2016.05.001","DOIUrl":"10.1016/j.pmu.2016.05.001","url":null,"abstract":"<div><h3>Purpose</h3><p>In Japan, the number of people who undergo fertility treatment is increasing; however, the absence of a legal regulatory framework concerning Assisted Reproductive Treatment (ART) results in a number of ethical issues. Some doctors violate existing guidelines and some couples who suffer from infertility go abroad in order to use medical treatments that are not allowed in Japan. In this paper, we introduce current issues and conditions and consider five major ethical challenges regarding ART.</p></div><div><h3>Study</h3><p><span>We researched current ethical issues and point out five major ethical issues regarding ART: (1) Issues arising when the oocyte donor and person giving birth are not the same, (2) issues related to </span>posthumous assisted reproduction<span> (PAR), (3) issues related to prenatal diagnosis (PD), (4) issues associated with sexual minorities starting a family, and (5) issues related to the rights of children born from ART to know their origins. We examined existing theories and summed them up.</span></p></div><div><h3>Results</h3><p>We provide a specific discussion on five major ethical challenges considering Japanese laws and court cases. We found that due to the absence of a legal framework for ART, there is likely to be an increase in contradictions between the use of outdated legal precedents and the technical developments of ART.</p></div><div><h3>Conclusions</h3><p>In modern Japan, legislation on ART urgently needs to be prepared. Such laws must sufficiently take into consideration the human rights of the next generation. The welfare of the child should be afforded the utmost respect.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"5 ","pages":"Pages 21-26"},"PeriodicalIF":0.0,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2016.05.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73716919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Improvised prophecy using regularization method of machine learning algorithms on medical data 基于正则化方法的机器学习算法在医疗数据上的即兴预言

Personalized Medicine Universe Pub Date : 2016-07-01 DOI: 10.1016/j.pmu.2015.09.001

Vadamodula Prasad , T. Srinivasa Rao (Dr) , P.V.G.D. Prasad Reddy (Prof)

引用次数: 9

New era in personalized medicine 个性化医疗的新时代

Personalized Medicine Universe Pub Date : 2016-07-01 DOI: 10.1016/j.pmu.2016.04.001

Hiroyuki Abe M.D, PhD, FACC (Editor-in-Chief, President)

引用次数: 3

Evolution of autologous endothelial progenitor cell therapy for tissue regeneration and vasculogenesis 自体内皮祖细胞治疗组织再生和血管发生的进展

Personalized Medicine Universe Pub Date : 2016-07-01 DOI: 10.1016/j.pmu.2016.04.002

Hiroko Hagiwara, Rica Tanaka

{"title":"Evolution of autologous endothelial progenitor cell therapy for tissue regeneration and vasculogenesis","authors":"Hiroko Hagiwara, Rica Tanaka","doi":"10.1016/j.pmu.2016.04.002","DOIUrl":"10.1016/j.pmu.2016.04.002","url":null,"abstract":"<div><p><span><span><span>Endothelial progenitor cell (EPC) transplantation therapy is a promising method in the field of regenerative therapy. EPCs, which were identified in adult peripheral blood, have the ability to differentiate into </span>endothelial cells<span> (ECs). Because of the potential for EPCs to promote tissue regeneration, transplantation of autologous EPCs is now recognized as a novel therapeutic option for </span></span>revascularization<span> and blood vessel repair in ischemic diseases, diabetic refractory limb </span></span>ulcers<span><span>, and other conditions. However, aging and various conditions and disease states, such as diabetes and arteriosclerosis<span>, are associated with reduced numbers and dysfunction of EPCs, which may result in decreased efficacy of autologous therapies. Therefore, in order to achieve better clinical outcomes in the treatment of a variety of conditions and diseases, further advances in regenerative therapies utilizing EPCs are required. In this review, we describe the potential roles of EPCs in </span></span>vasculogenesis and tissue regeneration. We focus on the development of EPC-based treatments and provide insights into the future of regenerative therapies utilizing EPCs for tailor-made medicine.</span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"5 ","pages":"Pages 8-15"},"PeriodicalIF":0.0,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2016.04.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88540988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Computed tomography-guided balloon-assisted endovascular recanalization and angioplasty in Leriche syndrome 计算机断层扫描引导球囊辅助血管内再通和血管成形术治疗Leriche综合征

Personalized Medicine Universe Pub Date : 2016-07-01 DOI: 10.1016/j.pmu.2015.11.002

Yukihiro Hama , Tatsumi Kaji

引用次数: 2

An evidence-based review: Anti-obesity effects of Coleus forskohlii 一项基于证据的综述:黄菖蒲的抗肥胖作用

Personalized Medicine Universe Pub Date : 2016-07-01 DOI: 10.1016/j.pmu.2016.02.001

Seika Kamohara

{"title":"An evidence-based review: Anti-obesity effects of Coleus forskohlii","authors":"Seika Kamohara","doi":"10.1016/j.pmu.2016.02.001","DOIUrl":"10.1016/j.pmu.2016.02.001","url":null,"abstract":"<div><h3>Background</h3><p><em>Coleus forskohlii</em><span> (Lamiaceae) is an Indian plant that has been used in traditional Indian medicine, Ayurveda. In the recent years, </span><em>C. forskohlii</em><span> extract has been used as a functional food for treating obesity and for promoting healthy weight management.</span></p></div><div><h3>Purpose</h3><p>The purpose of this review is to evaluate the anti-obesity effects of <em>C. forskohlii</em>.</p></div><div><h3>Study selection</h3><p>We conducted a comprehensive literature search by using electronic databases, including PubMed, MEDLINE, and the Cochrane database, for all articles published up to July 2015 and by handsearching using Google Scholar. The search terms used to obtain relevant articles included <em>C. forskohlii</em>, dietary supplement, weight loss, and overweight/obesity. There were no limitations of language and time.</p></div><div><h3>Results</h3><p>We identified 7 clinical studies; of those, 4 were randomized, double-blind, placebo-controlled studies and the others were open-label studies. The <em>C. forskohlii</em> extract had a significant benefit on body composition in overweight/obese subjects. No major adverse events were reported.</p></div><div><h3>Conclusion</h3><p>The <em>C. forskohlii</em> extract showed a substantial effect on weight loss and was safe and effective in reducing body fat in overweight/obese people. However, additional trials with high quality are required to establish a high level of evidence for the appropriate use of <em>C. forskohlii</em> extract as a personalized supplement and/or a pharmacological intervention.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"5 ","pages":"Pages 16-20"},"PeriodicalIF":0.0,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2016.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88301308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

An attempt to design optimal personalized exercise prescriptions using the KEIO-SENIOR treadmill protocol for patients with type 2 diabetes 尝试使用KEIO-SENIOR跑步机方案为2型糖尿病患者设计最佳个性化运动处方

Personalized Medicine Universe Pub Date : 2016-07-01 DOI: 10.1016/j.pmu.2015.12.001

Toshihide Kawai

{"title":"An attempt to design optimal personalized exercise prescriptions using the KEIO-SENIOR treadmill protocol for patients with type 2 diabetes","authors":"Toshihide Kawai","doi":"10.1016/j.pmu.2015.12.001","DOIUrl":"10.1016/j.pmu.2015.12.001","url":null,"abstract":"<div><p><span><span>We evaluated the effectiveness of new treadmill protocol KEIO-SENIOR. Fifty Japanese patients with diabetes (mean ± standard deviation age, 52.7 ± 11.7 years) had undergone medical examinations using the KEIO-SENIOR protocol. The protocol, for the exercise test, was as follows: the treadmill speed was initially set at 3.2 km/h. The grade was set at 0% initially, and was subsequently increased by 3% every 2 min until 10 min. After that, the grade was not changed; however, the speed was increased by 0.8 km/h every 2 min until the end of the test. The end-points of the test included reaching the target heart rate (THR: 0.85 × [220 − age]); symptoms, such as shortness of breath and leg fatigue; increase in a blood pressure; changes in ECG. The average stage reached by the patients at the end-point was 7.3 ± 1.7, and the average exercise endurance time was 832.1 ± 206.1 s. Regarding end-points, 31 subjects reached the THR and 19 developed the described symptoms. Based on these findings, for subjects who reached the THR, we designed an exercise prescription for each patient based on the heart rate equivalent to 50% of the maximum oxygen consumption using the formula of Karvonen. For others, we prescribed an exercise program based on the optimal heart rate and pace, with reference to the heart rate at the end-point. After 6 months, significant improvements in the blood pressure, </span>body mass index (changed from 27.7 ± 5.4 to 27.1 ± 5.3 kg/m</span><sup>2</sup><span> [p = 0.009]), and HbA1c<span> (changed from 7.8 ± 2.0 to 7.2 ± 1.8% [p = 0.011]) were observed. In conclusion, our results suggest that this protocol, the main purpose of which was not to detect coronary ischemia, was a useful tool to evaluate physical fitness and to prescribe exercises for middle-aged or elderly Japanese patients.</span></span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"5 ","pages":"Pages 27-31"},"PeriodicalIF":0.0,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.12.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81392476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Perspectives on targeting the phosphatidylinositol 3-kinase pathway for personalized medicine in endometrial and ovarian cancers 靶向磷脂酰肌醇3-激酶途径在子宫内膜癌和卵巢癌个体化治疗中的研究进展

Personalized Medicine Universe Pub Date : 2016-07-01 DOI: 10.1016/j.pmu.2016.03.001

Katsutoshi Oda, Yuji Ikeda, Tomoko Kashiyama, Aki Miyasaka, Kanako Inaba, Yuichiro Miyamoto, Osamu Wada-Hiraike, Kei Kawana, Yutaka Osuga, Tomoyuki Fujii

{"title":"Perspectives on targeting the phosphatidylinositol 3-kinase pathway for personalized medicine in endometrial and ovarian cancers","authors":"Katsutoshi Oda, Yuji Ikeda, Tomoko Kashiyama, Aki Miyasaka, Kanako Inaba, Yuichiro Miyamoto, Osamu Wada-Hiraike, Kei Kawana, Yutaka Osuga, Tomoyuki Fujii","doi":"10.1016/j.pmu.2016.03.001","DOIUrl":"10.1016/j.pmu.2016.03.001","url":null,"abstract":"<div><p>Endometrial and ovarian cancers show similar genetic and pathological backgrounds. In particular, high frequencies of activating mutations in the phosphatidylinositol 3-kinase (PI3K) pathway, including mutations in <em>PIK3CA</em> and <em>PTEN</em><span>, are found in both estrogen-dependent endometrial cancer (type I endometrioid carcinomas) and ovarian clear cell and endometrioid carcinomas. In this review, we focus on the PI3K pathway as a potential molecular target for personalized therapies in endometrial and ovarian cancers. We found that targeting the PI3K/mammalian target of rapamycin (mTOR) pathway produced anti-tumor effects in endometrial cancer upon suppression of the PI3K pathway. The presence of </span><em>KRAS</em><span> mutations may be a marker for resistance to the inhibition of the PI3K/mTOR pathway. However, the combination of a PI3K/mTOR pathway inhibitor and a MAPK<span><span><span> pathway inhibitor, such as a MEK inhibitor, has been shown to suppress </span>cell proliferation synergistically in certain endometrial cancers. In addition, PI3K/mTOR pathway inhibition sensitized endometrial </span>cancer cells<span> to ionizing radiation and produced anti-tumor effects in ovarian clear cell carcinomas in both </span></span></span><em>in vitro</em> and <em>in vivo</em><span> studies. Moreover, inhibition reduced the phosphorylation levels of MDM2 (a negative regulator of TP53), stabilized TP53, and induced TP53-mediated apoptosis. The activation of TP53 was associated with increased phosphorylation of TP53 on Ser-46, and its downstream target genes, such as </span><em>TP53AIP1</em><span>. These findings demonstrate that targeting of the PI3K pathway in both endometrial and ovarian clear cell carcinomas warrants further investigation, including in clinical trials.</span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"5 ","pages":"Pages 3-7"},"PeriodicalIF":0.0,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2016.03.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91517300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0